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ABSTRACT The aim of this study was to describe and analyze changes in the definition of 
diabetes as a disease and the relationship between these changes and subsequent modifi-
cations in the therapeutic management of the disease. A content analysis was performed 
using articles, guidelines, and consensuses published by the Argentina Diabetes Society 
and the Latin American Diabetes Association between 1980 and 2010. The different clas-
sifications, values used to define a person as diabetic, and treatments were assessed and 
the changes and modifications discovered were critically analyzed using categories such 
as medicalization, risk and lifestyles. As a result of the analysis we can observe how the 
growing process of medicalization, the dependence on the scientific knowledge of cen-
tral countries, the interests of the pharmaceutical industry, and the crucial role played by 
pharmacological treatments are all inscribed within the management of diabetes, which 
can be made visible through the changes that have taken place over the last 30 years.
KEY WORDS Diabetes Mellitus; Medicalization; Risk; Life Style; Chronic Disease; 
Practice Guideline.
RESUMEN El objetivo de este trabajo es describir y analizar los cambios en la 
definición de la diabetes como enfermedad y la relación con las transformaciones en 
su abordaje terapéutico. Se realizó un análisis de contenido sobre los artículos, guías 
y consensos publicados por la Sociedad Argentina de Diabetes (SAD) y la Asociación 
Latinoamericana de Diabetes (ALAD) entre los años 1980 y 2010. Se desagregaron las 
diferentes clasificaciones, los valores considerados normales para definir a una persona 
como diabética y el tratamiento, analizando críticamente los cambios y modificaciones 
encontrados con el auxilio de categorías como medicalización, riesgo y estilos de 
vida. Como resultado del análisis hemos podido observar cómo el creciente proceso 
de medicalización, la dependencia con respecto al conocimiento científico de países 
centrales, los intereses de la industria farmacéutica y el lugar central del tratamiento 
farmacológico se inscriben en el abordaje de la diabetes y se hacen visibles a través de 
los cambios sucedidos en los últimos 30 años. 
PALABRAS CLAVES Diabetes Mellitus; Medicalización; Riesgo; Estilo de Vida; Enfermedad 
Crónica; Guía de Práctica Clínica.
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INTRODUCTION
In central countries, the current prevalence 
of diabetes is thought to exceed 7% in the adult 
population (1). Moreover, between 30% and 50% 
of people who suffer from this health problem 
are not aware of it (2). In Argentina, a national 
diabetes prevalence of 8.4% was registered in 
the National Survey of Risk Factors carried out in 
2005. In 2009, a second survey showed the preva-
lence climbing to 9.6%, with only 55.2% of those 
affected receiving some type of treatment (3). 
Diabetes is the fifth leading cause of death in 
women aged between 45 and 64 years, and the 
fourth and sixth cause of death among women and 
men over 65, respectively (3).
This problem has therefore become of crucial 
importance to the health care system, due to its 
high prevalence, its increasing trend, the high 
direct and indirect costs that the disease produces 
and the serious consequences of the disease, 
which may endanger the lifespan and quality of 
life of the population (3).
In that sense, many changes have taken place 
during the last 30 years in the management and 
treatment of diabetes: on the one hand, the values 
considered normal have decreased (which has 
led to an increase in diabetes diagnoses) and, on 
the other hand, diabetes has been increasingly 
medicalized.
Therefore, the aim of this work (a) is to de-
scribe and analyze the changes in the definition 
of diabetes as a disease and in its treatment ac-
cording to the guidelines and consensuses pub-
lished by the Argentine Diabetes Society (SAD) 
[Sociedad Argentina de Diabetes] and the 
Latin American Diabetes Association (ALAD) 
[Asociación Latinoamericana de Diabetes] be-
tween 1980 – when the first international clas-
sification was released – and 2010, in order to 
reflect upon the different ways of managing this 
health problem in Argentina. 
Particularly, a question is raised concerning 
the relationship existing between the changes 
proposed by these two scientific societies and 
the medicalization of diabetes as a health care 
problem in the last 30 years.
On epidemiology and medical consensuses
Starting in the second half of the 20th century, 
chronic disease epidemiology or risk epidemi-
ology gained importance as a new epidemiological 
paradigm. It aims to establish measures of risk at 
the individual level in the population, thereby re-
lating exposure to risk factors with the production 
of disease. The interventions to be implemented 
seek to control these risk factors through changes 
in people’s lifestyles (4). Although risk epidemi-
ology is at present the predominant epidemio-
logical theory, it has been questioned since the 
1980s mainly for its difficulty in explaining and 
promoting successful interventions regarding se-
rious health concerns, such as cardiovascular dis-
eases, alcoholism or violence (4).
Within the framework of risk epidemiology, 
the concept of evidence-based medicine (EBM) 
emerged in the 1980s from the Anglo-Saxon 
clinical epidemiology movement, in McMaster 
University, Canada. EBM is specially related to 
scientificist rationalism. According to Castiel, “it 
is based on the idea of objectivity, reducing the 
universe of the observable to the quantifiable […] 
discounting the non-quantifiable features that give 
meaning to practice” (5 p.120).
The information resulting from scientific re-
search studies that use EBM methodology is com-
municated to healthcare professionals through 
“clinical practice guidelines” published by dif-
ferent scientific societies. These guidelines are de-
veloped in a systematic manner in order to help 
doctors decide about the most appropriate care 
to provide in concrete clinical situations. Three 
methods are used for the development of these 
guidelines: experts’ opinions, consensuses and 
evidence-based methods (6). Included in this line 
of work are the consensuses and articles found 
in the journals of the Latin American Diabetes 
Association, in which it is specifically stated that 
they were carried out in accordance with EBM 
methodology. A level of evidence is assigned to 
each recommendation depending on the type of 
epidemiological study carried out, based on its 
design, methodology and results analysis. As a 
consequence, studies are given a level of evidence 
from 1 to 4 or “others,” where level 1 represents 
the recommendations arising from meta-analyses 
and controlled clinical trials and level 4 represents 
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the results of cohort or case-control studies, while 
“others” includes case series and experts’ opinions. 
These levels are then assigned categories of rec-
ommendation, ranging from AA to D, where the 
first category signifies “optimum evidence for rec-
ommendation,” with at least one level 1 evidence, 
and D indicates that “evidence is insufficient or 
non-existent” (2 p.74).
In this way, clinical experience is no longer 
enough; scientific evidence is mandatory in order 
to make accurate clinical decisions. With this ap-
proach the value of experience and experts be-
comes hazy, as randomized experimental studies 
and meta-analyses are prioritized. 
The aim of this discussion is not to adopt 
an anti-scientific stance, as some developments 
were and are able to offer better health condi-
tions to people who have access to these benefits. 
Moreover, science has been able to provide tech-
nical and technological answers to many health 
problems. As Marcia Angell states (7), it was 
thanks to academic and industrial research and 
development that many good, effective drugs are 
now available:
There is no doubt that many people live better 
and longer thanks to them. However, they 
should be prescribed carefully and only when 
necessary; and doctors’ opinions – about 
when they should be prescribed – should be 
based on true indications and real research 
studies rather than on commercial promotion 
which pretends to be both of them. (7 p.192) 
[Own translation]
It is necessary to recognize that clinical trials 
made possible the commercialization of medi-
cines that have benefited humanity, but it cannot 
be denied that the number of clinical trials (which 
so far have not been quantified) responds not to 
scientific aims but economic purposes (8).
METHODOLOGICAL CONSIDERATIONS
To carry out this study, all publications of the 
Argentine Diabetes Society’s Revista SAD and of 
the Latin American Diabetes Association’s Revista 
de la ALAD were collected. Both are scientific 
societies and, as such, are specialist associations 
(of diabetes in this case) that aim at presenting 
and disseminating the results of research studies 
through publications and conferences. 
Both collections were reviewed starting with 
their first publications: in 1967 for Revista SAD 
and 1993 for Revista de la ALAD. The search 
was carried out in different libraries of the City 
of Buenos Aires: the Juan José Montes de Oca 
Central Library of the Faculty of Medicine of 
Universidad de Buenos Aires and the libraries of 
the Argentine Medical Association and Argentine 
Diabetes Society. The latter was the most com-
plete, and it was possible to access there the print 
versions of the entire collections of both journals. 
Research was also carried out online, as virtual 
access to the publications of Revista de la ALAD 
since 2006 was possible. However, Revista SAD 
was not accessed virtually given that subscription 
was required. 
The archive material was searched for con-
sensuses or guidelines involving classification, di-
agnosis and/or treatment of diabetes, with general 
management guidelines. As a result of this search, 
three articles were found in Revista de la ALAD 
and five in Revista SAD.
The study was carried out according to content 
analysis methodology (9) in two diachronic lines: 
one permitted the chronological reconstruction 
of changes in the therapeutic management of dia-
betes; the other was focused on understanding the 
meanings and relationships surrounding the changes 
produced, by grouping the material into two central 
themes (classifications and terminology). The way 
the terminology and the categories used to define 
diabetes – as well as the different classifications of 
this health problem – have changed throughout 
the years was analyzed. The successive laboratory 
values considered normal were analyzed in each 
category. Both so-called therapeutic changes in life-
style as well as drug therapy were also analyzed. 
In order to examine the new classifications 
and new values used for establishing a diagnosis, 
articles published by Revista SAD were used, the 
contents of which are centered on the emerging 
changes in these categories. In order to analyze 
diabetes treatment, Revista de la ALAD was pri-
marily used, as the topic was more thoroughly 
covered in this journal. 
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RESULTS
Articles from Revista SAD
The five articles analyzed from Revista SAD 
were published after the changes proposed by 
the World Health Organization (WHO), the 
National Diabetes Data Group and the American 
Diabetes Association (the latter two organizations 
are from the United States). What is published 
in such articles are the proposals and debates 
regarding certain recommendations, outlined as 
discussions and not as strict recommendations or 
instructions.
The first article found in Revista SAD is en-
titled “Clasificación de la diabetes” [Diabetes 
classification] and was published in 1982 based 
on the proposals of two meetings of diabetes ex-
perts: one by the National Diabetes Data Group, 
including diabetes specialists from the USA and 
Europe, held in April, 1978; and the other by the 
WHO, held in 1979. Categories, diagnostic cri-
teria and diabetes terminology were reviewed in 
both meetings (10).
Later, in 1997, when the American Diabetes 
Association published a new report, Revista SAD 
published two articles outlining the new diag-
nosis criteria proposed. The first was entitled 
“Diagnóstico de diabetes mellitus: ¿Necesitamos 
nuevos criterios?” [Diagnosis of diabetes mellitus: 
do we need new criteria?] (11) and the second was 
entitled “Informe del comité de expertos para el 
diagnóstico y clasificación de diabetes mellitus” 
[Expert committee report on the diagnosis and 
classification of diabetes mellitus] (12).
In 1998 another article was published, en-
titled “Definición, diagnóstico y clasificación de 
la diabetes mellitus y sus complicaciones. Parte 1: 
Diagnóstico y clasificación de la diabetes mellitus. 
Informe preliminar de un comité de consulta de 
la OMS” [Definition, diagnosis and classification 
of diabetes mellitus and its complications. Part 1: 
Diagnosis and classification of diabetes mellitus. 
Preliminary report from a WHO advisory com-
mittee], where conclusions of a new consultancy 
commissioned by the WHO were outlined (13).
Finally, the last article found in this journal 
was published in 2007, entitled “Consenso sobre 
criterio diagnóstico de la glucemia alterada en 
ayunas” [Consensus on the diagnosis criterion 
for impaired fasting glucose]. It focused on the 
reasons why the American Diabetes Association 
had decreased the cut-off values for impaired 
fasting glucose and listed the recommendations 
proposed by SAD (14).
Articles from Revista de la ALAD
From 1992 to 2010, three guidelines or 
consensuses were published in Revista de la 
ALAD. The first was published in 1998 and was 
entitled “Consenso sobre la prevención, control 
y tratamiento de la diabetes mellitus no insulin-
odependiente” [Consensus on the prevention, 
control and treatment of non-insulin dependent 
diabetes] (15). A group of subject-matter experts 
was selected, with the purpose of standardizing 
the prevention, diagnosis, control and treatment 
measures of non-insulin dependent diabetes mel-
litus in Latin America. 
The next ALAD consensus was published 
in 2000 as “Guías ALAD para el diagnóstico y 
manejo de la diabetes mellitus tipo 2 con me-
dicina basada en evidencia” [ALAD guidelines for 
the diagnosis and management of type 2 diabetes 
mellitus using evidence-based medicine]. The text 
explains that such an update was necessary due to 
the results of some key studies, such as the United 
Kingdom Prospective Diabetes Study – which 
followed 4,075 patients recently diagnosed with 
type 2 diabetes for an average of 10 years – and 
the development of new drugs for the treatment 
of diabetes. In this framework, ALAD once again 
convened a group of specialists in order to create 
the new guidelines (16).
The third and last set of guidelines found was 
published in 2006 under the title “Guías ALAD 
de diagnóstico, control y tratamiento de diabetes 
mellitus tipo 2” [ALAD guidelines for diagnosis, 
control and treatment of type 2 diabetes mellitus] 
(2). The main reason for updating the recom-
mendations published in 2000 was related to the 
pharmacological management of diabetes, and 
justified by the fact that the goals aimed at con-
trolling some clinical parameters had become
increasingly strict as the studies show the 
benefit obtained […] Therefore, other alter-
natives are being proposed to achieve these 
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goals more quickly and effectively using more 
aggressive strategies such as the early admin-
istration of oral antibiotics and basal insu-
lintherapy. (2 p.5) [Own translation]
In these guidelines it is explained that the 
ALAD has remained in alignment with changes 
that other international diabetes organizations 
have made, with the objective of offering updated 
clinical practice recommendations to diabetes 
care teams (2). 
On diabetes classifications and values 
considered normal: reconstructing the 
history
As concepts are used over time, they are in-
evitably modified by those who use them and ac-
cording to certain objectives. Thus, diabetes – like 
so many other health issues – faces changes in its 
classifications, in the ways it is named, or in the 
ways it is diagnosed (Figure 1).
Therefore, taking into account the interna-
tional recommendations, the analyzed scientific 
societies proposed several changes. In order to 
look at these changes, three main dimensions 
will be analyzed: first, the successive classifica-
tions proposed to categorize patients as diabetic; 
second, how categories prior to diabetes have 
been modified over the years; and finally, what 
have been considered the “normal” blood glucose 
levels at which to diagnose a patient as diabetic at 
different moments in time.
Classifications
The first classification in 1982 was related to 
successive stages of this health problem: “predia-
betes, chemical diabetes and clinical diabetes” (10 
p.4). Several years later, in 1988, the Argentine 
Diabetes Society stated that the widely accepted 
first classification was first introduced by the 
WHO in 1980, “putting into order a chaotic situ-
ation in which the nomenclature and diagnostic 
criteria showed great variation” (13 p.212).
First international 
classification of 
diabetes (WHO and 
NDDG)
Normal 
fasting blood 
glucose level< 
140mg/dl 
Changes 
introduced by 
the ADA
New category: “impaired fasting glucose” 
(IFG)
Normal level: 110-126 mg/dl
New fasting blood glucose level: <126 mg/dl
Minor changes 
by the WHO
ADA/WHO 
parallel 
consultation for 
a new 
classification
New type of 
diabetes called 
“malnutrition-rel
ated diabetes 
mellitus”
New normal IFG 
level: 100-126 
mg/dl
Reintroduction of 
the term 
“prediabetes”
1979/1980 1985 19981997
Introduction of 
changes by the 
WHO
1999
New proposal made by 
the ADA
2003 2008
Change in 
pharmacological 
treatment: 
Metformin for 
pre-diabetic 
patients with 
risk factors
Figure 1. Changes made over the years in diabetes classification and normal laboratory levels 
according to the changes proposed by scientific societies. 1979-2008.
Source: Own elaboration based on the analyzed consensuses of the Argentine Diabetes Society and the Latin American Diabetes Association (12,13,14).
WHO = World Health Organization. NDDG = National Diabetes Data Group. ADA = American Diabetes Association. IDD = insulin-dependent diabetes. 
NIDD = non-insulin-dependent diabetes.
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The classification introduced in 1979 and 
1980 by the NDDG and the WHO divides patients 
into two large groups. The first group is called 
“clinical classes,” in which the classification de-
pends on the pharmacological treatment being 
undertaken, that is to say, if the patient does or 
does not “depend” on insulin: insulin-dependent 
diabetes mellitus (IDD) or type 1 and non-insulin-
dependent diabetes mellitus (NIDD) or type 2. 
The second group, called “statistical risk classes,” 
comprises
…a category which has potential risk as it 
includes individuals who may at some point 
alter their glucose metabolism on account of 
ethnic, genetic, obstetric or immunity reasons 
(10 p.6). [Own translation]
The following classification was published in 
1985, in which
…the terms type 1 and type 2 were omitted, 
keeping the terms IDD and NIDD, and a new 
type of malnutrition-related diabetes mellitus 
(MRDM) was introduced (13 p.216). [Own 
translation]
Later, in 1997, both the WHO and the 
American Diabetes Association made a new pro-
posal in which the classifications were based on 
etiology. The Argentine Diabetes Society explains:
…of particular importance is the fact of 
replacing the system that classified diabetes 
according to the type of pharmacological 
treatment used for its control, for another 
system based – whenever possible – on 
the etiology of the disease (12 p.96). [Own 
translation]
This classification “eliminates the concepts 
of insulin-dependent diabetes mellitus and non-
insulin-dependent diabetes mellitus and its ac-
ronyms” (12 p.99) because “these names caused 
confusions, and patients were frequently classified 
according to the disease treatment instead of its 
etiology” (12 p.99). The 1997 classification is still 
in force (Table 1).
Prior to diabetes: other categories?
The first analyzed consensus published by the 
Argentine Diabetes Society, in 1982, mentions the 
creation of a “new entity, different from diabetes 
mellitus” (10 p.7), known as impaired glucose tol-
erance (IGT), established by the National Diabetes 
Data Group. This category includes patients that 
show “plasma glucose levels between normal test 
levels and those corresponding to diabetes mel-
litus” (10 p.7). It is explained that, within this group:
…although in some cases it may be a stage 
in the progression towards diabetes mellitus, 
in others the glucose curve may become 
stabilized and, often, remain unchanged for 
an indefinite period of time. (10 p.7) [Own 
translation]
The classification carried out prior to that 
of the international consensus (prediabetes, 
chemical diabetes, clinical diabetes) included a 
category calling this type of situation prediabetes 
(8,10).
In 1997, the American Diabetes Association 
and, later in 1999, the WHO introduced a new 
category to identify individuals at greater risk of 
suffering from diabetes: impaired fasting glucose 
(IFG), involving fasting glucose levels between 
110 and 126 mg/dl (14). This category, rather than 
a class, as in the previous classification, is catego-
rized as a stage in the natural development of car-
bohydrate metabolism disorders.
According to the Argentine Diabetes Society, 
people with impaired fasting glucose “have a 
higher risk of progressing towards diabetes and 
macrovascular disease” (13 p.219). This so-
ciety states that both impaired fasting glucose 
and impaired glucose tolerance are not clinical 
conditions in themselves but risk categories for 
diabetes and/or future cardiovascular diseases, 
serving as indicators or markers of increased risk 
(13). They add that
...impaired glucose tolerance was reclassified 
as a stage of impaired glucose regulation, 
because it can be observed in any hypergly-
cemic disorder and it is not in itself diabetes. 
(13 p.218) [Own translation]
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When in 2003 the American Diabetes 
Association recommended lowering the 
threshold level for the diagnosis of impaired 
fasting glucose to 100 mg/dl (14), this cri-
terion was not universally accepted, and many 
diabetes-related associations expressed their 
disagreement. Given the consequences of 
this recommendation, the Argentine Diabetes 
Society “called in a group of experts order to 
analyze the available evidence, and based on 
such evidence, to give their opinion on the 
issue” (14 p.102).
In relation to the diagnostic values for this cat-
egory, the Argentine Diabetes Society stated that 
“the diagnostic level threshold regarding fasting 
glycemia should not be lowered” (14 p.103) and 
recommended:
Table 1. Classification of diabetes according to the scientific societies, 1980, 1985 and 1997.
Classification, 1980. Classification, 1985. Classification, 1997.
1. Clinical 
classes
a. Diabetes 
mellitus
Type 1 Insulin-
dependent dia-
betes mellitus
1. Clinical 
classes
a. Diabetes 
mellitus
Insulin-depen-
dent diabetes 
mellitus
1. Type 1 
diabetes
 ▪ Immune mediated
 ▪ Idiopathic 
Type 2 
non-insulin-
dependent 
diabetes 
mellitus
i. Non-obese
ii. Obese
iii. Other types 
including 
diabetes 
mellitus 
associated 
with certain 
conditions and 
syndromes
Non-insulin-
dependent 
diabetes 
mellitus 
i. Non-obese
ii. Obese
iii. Other types 
including 
diabetes 
mellitus 
associated 
with certain 
conditions and 
syndromes
2. Type 2 diabetes
3. Other 
specific 
types of 
diabetes
 ▪ Genetic defects
 ▪ Diseases of the 
exocrine pancreas
 ▪ Endocrinopathies
 ▪ Drug- or chemical-
induced
 ▪ Infections
 ▪ Other genetic 
syndromes sometimes 
associated 
iv. Malnutrition-
related diabetes 
mellitus
b. Impaired 
glucose 
tolerance
i. Non-obese
ii. Obese
iii. Other types 
including 
diabetes 
mellitus 
associated 
with certain 
conditions and 
syndromes
b. Impaired 
glucose 
tolerance 
i. Non-obese
ii. Obese
iii. Diabetes 
mellitus 
associated 
with certain 
conditions and 
syndromes
c. Gestational diabetes c. Gestational diabetes mellitus 4. Gestational diabetes mellitus
2. Statistical 
risk classes
a. Previous abnormality of 
glucose tolerance
2. Statistical 
risk classes
a. Previous abnormality of glucose 
tolerance
b. Potential abnormality of 
glucose tolerance
b. Potential abnormality of glucose 
tolerance
Source: Own elaboration based on publications of the Argentine Diabetes Society (10 p.5, 12 p.100) and the World Health Organization (36 p.19).
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...keeping the original cut-off level for IFG 
(110 mg/dl) in individuals without diabetes 
risk factors and using a level of 100 mg/dl for 
patients with risk factors. (14 p.103) [Own 
translation]
Additionally, members of the Argentine 
Diabetes Association stated that the recommen-
dation would be upheld until such a time as 
more evidence for modifying it and promoting 
studies aimed at establishing its relevance using 
well-defined clinical parameters was available, in-
cluding the application of prevention strategies for 
diabetes and cardiovascular diseases “based pri-
marily on lifestyle changes and not on the use of 
drugs” (14 p.103).
Regarding one of the categories prior to dia-
betes, the consensus concludes that:
...the term “prediabetes” must not be used; 
it is better to replace it with “impaired 
fasting glucose” because, although pro-
gression towards diabetes occurs in certain 
cases, in others the condition remains 
stable for a long time and it has even been 
described that a group may present normal 
levels in subsequent tests. (14 p.102) [Own 
translation]
In 2006, the Latin American Diabetes 
Association also offered its view regarding the 
changes in terminology:
...the term prediabetes has once again come 
to be used to categorize those individuals 
who do not meet the criteria to be diagnosed 
as diabetic but have abnormal results in their 
diagnostic tests. These people are at high risk 
of developing diabetes and also have a higher 
risk of cardiovascular problems. [...] Some 
experts in this subject prefer the term “dys-
glycemia” or even the more descriptive term 
“impaired glucose regulation.” (2 p.13) [Own 
translation]
With regard to the levels considered 
normal for impaired fasting glucose, the Latin 
American Diabetes Association outlines the pro-
posal of other associations such as the American 
Diabetes Association, according to which the new 
diagnostic levels are between 100-125 mg/dl (2). 
In the analyzed text it is explained that such cri-
teria are recommended by the American Diabetes 
Association, however, the proposal of the ALAD 
itself, regarding whether or not these new di-
agnostic criteria should be adopted or whether 
the previous levels should be maintained, is not 
described.
Consequently, the creation of new concepts 
to refer to the “risk factors for developing diabetes 
and cardiovascular disease in the future” can be 
observed (12 p.107). Throughout the years, dif-
ferent names have been chosen depending on 
the historical moment or the scientific society 
involved: prediabetes, impaired or decreased 
glucose tolerance, impaired fasting glucose, 
glucose intolerance, dysglycemia, impaired 
glucose regulation. All of them refer to two types 
of situations: one is the fasting glycemia level and 
the other is the tolerance test that shows levels that 
are neither “abnormal” nor “normal.”
Therefore, it is possible to notice that the suc-
cessive classifications go hand in hand with the 
debates and proposals regarding health-disease 
management, the proposal of an early diagnosis 
and the detection of risk factors, and they are all 
within the framework of the currently prevailing 
epidemiological paradigm: “risk epidemiology.”
“Normal” and “abnormal” diagnostic levels
In 1982, the Argentine Diabetes Society listed 
certain procedures by which it is possible to di-
agnose diabetes mellitus (10 p.6):
a. By the clinical symptomatology of diabetes 
with evidence of fasting hyperglycemia. 
b. By a fasting plasma glucose level higher 
than 140 mg/dl, tested no less than two times 
consecutively.
c. When an oral glucose tolerance test (OGTT) 
shows, after 2 hours, a plasma glucose level 
higher than 200 mg/dl and an equal or higher 
level between 0 and 120 minutes.
In 1997, the Argentine Diabetes Society 
proposed new diagnostic criteria (12 p.108) 
which were modified according to the previous 
criteria recommended by the National Diabetes 
Data Group:
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a. Diabetes symptoms along with random 
plasma glucose levels ≥ 200 mg/dl.
b. Fasting glucose level > 126 mg/dl.
c. Two-hour post-load glucose level of 200 
mg/dl during the oral glucose tolerance test 
(OGTT).
In a subsequent document, the Argentine 
Diabetes Society mentions:
...the most important change, regarding the 
previous recommendations made by the 
WHO, is the decrease in the fasting glucose 
diagnostic level to 126 mg/dl, the previously 
considered level being ≥140 mg/dl. (13 
p.215) [Own translation]
According to the statements analyzed, there 
was a decrease in the normal levels of two param-
eters: fasting glucose level (from 140 mg/dl to 126 
mg/dl) and impaired fasting glucose level (from 
110 mg/dl to 100 mg/dl).
As we can see, agreement regarding the cat-
egories prior to diabetes is not established. This 
can be observed in how such categories are named 
and managed: the American Diabetes Association 
suggests starting with drugs in high risk patients at 
these clinical levels, while the Argentine Diabetes 
Society does not agree. Therefore, there is great di-
vergence both at a global and local level depending 
on which scientific society is used as a reference.
In Argentina, where there are no uniform 
guidelines used by health professionals, if local 
guidelines are taken into account, the normal 
fasting glucose level would be less than 110 
mg/dl. However, if the American Diabetes 
Association guidelines are followed, the level 
would be 100 mg/dl. Therefore, a person is or 
is not diabetic or “prediabetic” within the same 
country, even in the same city, depending on the 
professional who treats the patient.
In this sense, the consequences for patients 
diagnosed as diabetic must be taken into ac-
count, highlighting the “possible adverse effects, 
including psychological and economic damages 
caused by a diagnosis and treatment providing no 
medical benefits” (11 p.90).
It is true that the concept of normality “is not 
static and pacific, but rather dynamic and contro-
versial” (17 p.187). Moreover, since these levels 
are continuous variables, an artificial dichotomy 
is established such that an individual may have 
a “normal” glucose level one day and an “ab-
normal” value a day after. We overlook the fact 
that there is a person involved who was diagnosed 
with a disease that still has no cure. This implies 
the (“imperfect”) labelling of someone as having 
an “abnormality.”
All of this is related to the medicalization of 
diabetes, as in the background lies the potential 
profits of the pharmaceutical industry: starting a 
pharmacological treatment before the definitive 
diagnosis of diabetes implies an increase in the 
amount of drug consumers.
Individualized treatment and “therapeutic 
lifestyle changes” as an individual 
responsibility
Non-pharmacological treatment: “therapeutic lifestyle 
changes”
The analyzed consensuses first highlight 
“non-pharmacological measures” or “therapeutic 
lifestyle changes,” with proposals related to health 
education, physical activity and healthy habits. 
The Latin American Diabetes Association stresses 
that educational strategies are extremely important 
and must be used with the person with diabetes 
as well as his/her family members. In this way, an 
“educational plan” is justified because
...diabetes mellitus is a chronic disease that 
compromises all the aspects of a person’s 
daily life. Therefore, the educational process 
is essential for the treatment of a diabetic 
patient. (16 p.128) [Own translation]
The Latin American Diabetes Association sug-
gests that the mass media plays a very important role 
in the educational process of the community. It also 
mentions that both the basic knowledge of diabetes 
and the aspects related to the disease – referring 
to diabetes prevention and education – should be 
included in medicine and health sciences curricula 
(16). It proposes that a budget should be established 
for the education of diabetic patients within the of-
ficial programs for control and treatment of chronic 
diseases. At the same time, “the contributions of 
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the pharmaceutical industry to this end must be 
sought” (2 p.128).
Diet is outlined by the Latin American 
Diabetes Association as “the key pillar of the di-
abetes treatment” (2 p.21). Some features of the 
recommended diet are explained and certain 
goals for physical activity and recommendations 
regarding so-called healthy habits, referring exclu-
sively to smoking, are proposed (2).
Pharmacological treatment
In the consensus published by the Latin 
American Diabetes Association in 1998, it is rec-
ommended that
...as a primary therapeutic measure, it is 
important to try to reach a healthy weight. 
Within this group a three-month diet plan 
with periodic controls will be established 
before adding any possible drug treatment. 
If despite losing weight a suitable metabolic 
control is not reached, a treatment with bigu-
anide, thiazolidinedione or an alpha-gluco-
sidase inhibitor will be initiated. (15 p.17) 
[Own translation]
The subsequent consensus, published in 
2000, offers the same proposal as the previous 
consensus. However, it is explained that
...some patients require pharmacological 
treatment from the start, because they are 
clinically unstable or have a high level of 
decompensation that makes it possible to 
anticipate a poor response to an exclusively 
non-pharmacological treatment [...] pharma-
cological treatment can be initiated from the 
start as per the doctor’s judgement. (16 p.136) 
[Own translation]
In 2006, the Latin American Diabetes 
Association proposed:
...pharmacological treatment using antidia-
betic drugs should be initiated in any person 
with type 2 diabetes in whom the goals of a 
good glycemic control have not been achieved 
with therapeutic lifestyle changes (TLC) [...] 
In cases where the clinical conditions of a 
patient allow doctors to anticipate that this 
will happen, pharmacological treatment must 
be considered from the moment of diabetes 
diagnosis along with therapeutic lifestyle 
changes. (2 p.25) [Own translation]
In order to justify such a recommendation, 
the Latin American Diabetes Association men-
tioned the changes that had been recently pro-
posed by the American Diabetes Association and 
the European Association for the Study of Diabetes 
(EASD), stating that those scientific societies:
...have published an algorithm for the man-
agement of type 2 diabetes, where they 
propose that a metformin treatment must 
be initiated along with TLC in all patients 
with type 2 diabetes, considering that non-
pharmacological management ends up being 
insufficient in the first year of treatment. (2 
p.25) [Own translation]
“Therapeutic lifestyle changes” in diabetic pa-
tients are mentioned without considering that the 
lifestyle of each patient is in fact his or her life and 
not just a “style,” including the conditions of re-
production, working conditions, and the material 
conditions of existence of each human being. The 
concept of lifestyle has its origins in the concept of 
living conditions, which was developed outside of 
the realm of biomedicine: by Marxist thought, in 
relation to the mode of production and the general 
conditions of production (19); and in Weberian 
comprehensive sociology (18), articulating the 
social structure and individuals with a certain style 
in their daily life, personally and socially.
This concept was first posited as holistic 
and was subsequently reduced to personal risk 
behavior in the health sector. In this way, its ex-
planatory capacity was eliminated, casting aside 
both material and ideological conditions (20). 
Menéndez states that although it is true that a part 
of the population may be able to lower its specific 
risk, the ability to choose is reduced to individual 
behavior (20).
It must be borne in mind that risk as a con-
struct placed solely at the individual level presup-
poses – explicitly and implicitly – that the subject 
is a totally free being, with the capacity and ability 
to choose whether or not to smoke or eat healthy 
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food (20). However, there are certain social groups 
in which the ability to make certain choices is 
practically nonexistent. As Castiel and Álvarez 
Dardet state: “many people do not choose the life-
styles they lead. In reality there aren’t any options 
available, only possible survival strategies” (21).
It does not appear to be evident that eating 
appropriately, although a personal decision, is 
strongly conditioned by economic, advertising 
and social circumstances which do not always 
reflect personal choice (22). Therefore, these con-
texts are not taken into account when considering 
the disease management approach proposed by 
the analyzed scientific societies. As was previ-
ously mentioned, the articles from Revista de la 
ALAD were elaborated using the evidence-based 
medicine methodology, and make general recom-
mendations for all of Latin America. Such meth-
odology does not allow for the consideration of 
the particularities of each place: it is based on 
“scientific evidence” from studies carried out in 
other populations in other countries and trans-
lated directly to Latin American contexts. On the 
other hand, the articles from Revista SAD include 
general proposals related to classifications and 
names proposed by international organizations.
In the analyzed articles as well as in the journals 
and on the websites of these scientific societies, ad-
vertisements for pharmaceutical laboratories con-
cerning drugs or products aimed at “controlling” 
diabetes can be found. Moreover, at the end of the 
analyzed article published in 1998 by Revista SAD, 
an acknowledgement of the financial contribution 
received by some laboratories (Bayer and Novo 
Nordisk) appears. Similarly, the fragment shown in 
Figure 2 was found at the beginning of one of the 
articles published by Revista de la ALAD.
Based on the abovementioned articles, the 
Latin American Diabetes Association states that 
laboratories limited themselves to “providing 
medical literature during the evidence research 
stage” (2 p.3). Such provision is analyzed by 
Acknowledgements
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Doval, who discusses that the development of 
these guidelines is “normally constrained to the 
available published information” (23 p. 499), in 
which there are different factors that can lead to 
biased conclusions. Examples of these factors 
include the selection of studies to be submitted, 
which of these studies are then accepted for publi-
cation, the presence of duplicate publications that 
are difficult to detect, and the way in which the 
results are communicated (23).
Moreover, one of the articles from Revista de 
la ALAD, after suggesting the role the State plays 
in the education of individuals with diabetes, adds 
that “at the same time it is necessary to seek out 
the contributions of the pharmaceutical industry to 
this end” (16 p.128).
Consideration must be given to the interests 
of the pharmacological industry, which are not dif-
ferent from those of any other private company: 
that is, generating the greatest possible profit. 
Therefore, if investment is made in scientific re-
search, it is not off base to think that the aim of such 
research is to profit from the results. The problem 
is that the profit motive affects scientific research 
and subverts its essence (24). When profits are in-
volved, revenue-based financing and conflicts of 
interest arise, which – in the end – affect those who 
should be benefitted by such scientific progress: 
the population and, especially, those with greater 
difficulties accessing dignified healthcare services. 
Thus, Doval states that
The clinical research studies that are pub-
lished are increasingly designed, supported 
and financed by drug manufacturing com-
panies. Therefore, the question may arise as 
to whether, in addition to the power of such 
companies to decide that only that which 
might be profitable will be researched, there 
also exists the possibility of biases regarding 
the communication, publication and interpre-
tation of clinical findings. (23 p.498) [Ówn 
translation]
Efficacy focused on drugs is one of the fea-
tures that sustains diabetes treatment as well 
as many other health problems. The medi-
calization of these issues does not only in-
volve drug prescription as an essential part of 
healthcare workers’ actions, but also implies 
the demand for practices characteristic of this 
model by different sectors of society. Therefore, 
medicalization is directly related to the growing 
pharmacodependence of social groups (25).
FINAL COMMENTS
Medicalization of risk
On the one hand, the lack of agreement among 
the different scientific societies regarding certain 
changes, such as the names of certain categories 
or the levels considered normal proposed over 
the last five years, is surprising. This disagreement 
was clearly reflected in the last changes, when the 
American Diabetes Association proposed a return 
to the term “prediabetes” in the case of impaired 
fasting glucose and a decrease in the normal 
glucose level. On the other hand, this scientific 
society proposes that for certain “high-risk” groups 
it is necessary to start pharmacological treatment 
when prediabetes is diagnosed (26).
If we recall the definition of the stages prior 
to diabetes according to the analyzed articles from 
the Argentine Diabetes Association, patients with 
impaired fasting glucose “have a higher risk of 
progressing towards diabetes and macrovascular 
disease” (13 p.219). Furthermore, this scientific so-
ciety states that although “although in some cases it 
may be a stage in the progression towards diabetes 
mellitus, in others the glucose curve may become 
stabilized and, often, remain unchanged for an 
indefinite period of time” (10 p.7). Moreover, the 
concept of risk refers to “the probability of the oc-
currence of an event” (27 p.89). Thus, we can see 
that these stages are considered risks and, as such, 
they do not always occur.
Consequently, these changes lead to an 
increase in the medicalization of this health 
problem, since medicating individuals pertaining 
to “high risk” groups is proposed, although they 
have not yet fallen into the category of diabetes 
and their glucose levels could stabilize. Thus, we 
face another situation in which we must include 
within the adverse effects of each treatment those 
related to the diagnosis and treatment of problems 
which many never actually occur (28).
Castiel and Álvarez Dardet state that there are 
some sectors of health sciences that:
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...started to collaborate strongly with cor-
porate strategies of the pharmaceutical 
industry to make the occurrence of disease 
a space that could be broadened, both in 
the present by creating new diseases and, 
through the notion of risk, also medicalizing 
the future. (28 p.462) [Own translation]
These authors comment that the idea of risk is 
related to “that sense of great insecurity of our age 
that seems to generate a search for predictability in 
relation to the possible scenarios and events that 
may happen to us” (28 p.462). This is the reason 
why we, as healthcare professionals as well as users, 
need clearer answers for each of the problems with 
which we are presented. We are influenced by the 
idea that “truth can only be obtained through an 
almost paroxysmal search for evidence” (28 p.462).
Medicalization and creation of new 
diseases
In this study we analyzed how normal glucose 
levels to categorize a person as diabetic were mod-
ified and how new categories prior to diabetes 
were created. Marcia Angell (7), when analyzing 
changes in normal blood pressure parameters, 
states that the drug markets aimed at blood pressure 
grew when the experts’ committee changed the 
definition of high blood pressure (hypertension), 
introducing a term called prehypertension: blood 
pressure between 120/80 and 140/90 mmHg. 
Previously, a level lower than 140/90 mmHg was 
considered to be normal. Thus, “overnight, people 
with blood pressures in this range found that they 
had a medical condition.” Angell adds that:
Although the panel recommended that prehy-
pertension generally be treated first with diet 
and exercise, human nature being what it is, 
many people will almost certainly prefer to 
be treated with drugs. That expansion in the 
definition will add millions of customers for 
blood pressure drugs – despite the absence 
of convincing evidence of their benefit in this 
group. (7 p.107)
Thus, changes in laboratory levels for diag-
nosis have significantly increased the number of 
patients now classified as having prehypertension 
or prediabetes (29). Homedes and Ugalde explain 
that “once there is an official modification of the 
parameters or thresholds of certain diseases and 
new diseases are created, the powerful marketing 
machine of the great innovative drug industry 
comes into motion to promote the sales of drugs 
for these health conditions” (29 p.317).
Drugs are not ordinary commodities; as a 
result, it can be suggested that their development 
and production should be guided by different 
criteria than those followed by other industries 
(29). Lorenzo and Garrafa state that “at present, 
the multinational pharmaceutical industry is one 
of the most powerful economic conglomerates 
on the planet” (30 p.167). The main drug patents 
belong to 15 companies and most clinical trials 
are related to chronic diseases (such as diabetes, 
asthma, dyslipidemia and hypertension). They 
conclude by affirming that this “generates a gen-
erally captive market, with business stability and 
continuous profitable growth” (30 p.167).
Medicalization and scientific research
Based on the analyzed articles, it is surprising 
to observe that a health concern such as diabetes 
– a disease known for centuries – has in the last 
thirty years undergone so many changes and 
raised so many debates regarding normal glucose 
levels, different denominations or the proper time 
to start treatment. This is not a feature exclusive 
to diabetes, but, as Silvia Ayçaguer (31) states, all 
scientific research is experiencing increasingly 
rapid changes. Both the speed at which techno-
logical advances occur as well as the amount of 
available information grow unstoppably. Similarly, 
healthcare professionals have many more oppor-
tunities to be informed, although this may become 
overwhelming (31).
Menéndez analyzes these changes in relation 
to how guidelines and published works become 
outdated increasingly quickly. Similarly, the time 
and number of tests that a new chemical product 
has to undergo are reduced in order to activate 
its launch into the market. These reductions help 
to sustain a systematic obliviousness regarding the 
negative consequences these products cause in 
the population (18). According to Menéndez:
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Research results gain autonomy from medical 
knowledge, and “are bought down” to doctors 
as instruments that only they can apply [...] 
Personal processes – both those of patients 
and of doctors (the clinical eye) – which were 
relevant in the doctor-patient relationship are 
increasingly disappearing in practice, due not 
only to the development of a medicine of the 
masses that is ruled by the criteria of produc-
tivity but also to the replacement of clinical 
conduct by pharmacological conduct, which 
makes drug prescription its main objective 
and its primary technical/professional identi-
fication. (32 p.26) [Own translation]
Pharmaceutical companies try to find new 
uses for their drugs, because in this way they can 
extend the sales monopoly granted by the relevant 
patent (29). Angell affirms that “the pharmaceu-
tical industry is not especially innovative [...] The 
great majority of ‘new’ drugs are not new at all 
but merely variations of older drugs already on the 
market. These are called ‘me-too’ drugs” (7 p.19).
Me-too drugs “generally target very common, 
lifelong conditions – like arthritis or depression 
or high blood pressure or elevated cholesterol. 
The conditions are not so serious that they are im-
minently lethal, but they don’t go away, either” 
(7 p.106). Therefore, many people will consume 
these drugs for many years, generating a constant 
sales volume. However, people who suffer from 
uncommon diseases, with a small market, or 
people suffering from short-lived diseases, such as 
many acute infections, are not the target of phar-
maceutical companies. Deadly diseases kill the 
consumer; therefore, drugs aimed at these diseases 
do not generally obtain great sales success (7).
Medicalization and technical/professional 
dependence
Ugalde and Homedes (8) analyze how 
clinical trials have been exported to low- and 
middle-income countries over the last years with 
the aim of increasing business and transferring 
risks to very poor people. When describing the 
situation in Latin American, the authors discuss 
how doctors’ recruitment of patients is facilitated 
by the fact that it is conducted in public health 
care services which tend to serve people with low 
incomes and low levels of education, along with 
the lack of free access to medication (8 p.143-4). 
As most are multicenter and multinational studies, 
local researchers do not analyze the information 
that arises from these studies; rather, it is the in-
dustry that gathers the results and “sends them to 
their headquarters […] usually located in a high 
income country, to be analyzed” (8 p. 143-4). 
Often, what is being tested are drugs for a chronic 
disease, where “there is no guarantee that those 
participants who enjoyed the benefits while the 
trial was conducted will have access to the drug 
in the future, as once the drug is released on the 
market it will be unaffordable to them” (8 p.144). 
This inequity, in which the most vulnerable 
sectors are those exposed to the risks caused by 
clinical trials, comes into contrast with the ben-
efits that the trials generate for transnational com-
panies, the professionals that work for them, and 
the consumers of high-income countries (8 p.145).
The study designs most commonly used for 
determining the efficacy of a treatment or pre-
ventive measure are controlled clinical trials and 
meta-analyses (33): both designs have the highest 
level of recommendation according to evidence-
based medicine methodology (2). The final goal 
of these types of studies is to be able to be gener-
alize the results beyond the study population (33). 
However, these studies may present problems re-
lated to their internal and external validity, con-
nected to the way in which subjects are chosen 
to participate in the study. To be useful clinically, 
results must have both internal and external va-
lidity; a justifiable concern has been raised re-
garding the fact that this validity tends to be poor 
in controlled clinical trials (34 p.90). There are 
certain limitations that may affect the external va-
lidity of these studies. Different types of diagnostic 
methods might be used, and there may be differ-
ences in access to the healthcare system among 
the different countries taking part in a clinical trial. 
Therefore, results may be different if presented sep-
arately or unified in a single clinical trial (36). The 
same may happen if there are differences in the 
way that participants are recruited: in health care 
centers with different levels of complexity or by 
physicians with different medical specialties (34). 
Differences in socioeconomic, geographic, ethnic 
or temporary conditions may exist between the 
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studied population and the target population 
(35), or between the onset and the outcome of 
the disease among the different populations. It 
is worth asking whether those conditions may 
have influence on the results, and, consequently, 
limit their generalizability (35). The aim of these 
studies is to determine the effect of the treatment, 
not to measure the benefits of treatment in clinical 
practice, therefore, it cannot be expected that the 
results of these types of studies are relevant for all 
patients and all settings (34).
It is true that many of the changes in the man-
agement of diabetes have been proposed by coun-
tries in the Northern Hemisphere, because most 
of the recommendations on the management of 
diabetes come from studies in that area. Thus, in a 
country like Argentina where local health care re-
search is scarce, we base treatment for many of the 
most prevalent health concerns on the “evidence” 
arising from studies carried out with the clear mark 
of the pharmaceutical industry, in which the gen-
eralization of results represents a problem, due to 
the differences existing in health care access and 
in socioeconomic and cultural conditions, which 
could have influenced the development and 
outcome of diabetes and other health problems.
We should therefore keep these debates in 
mind when defining changes in the management 
of a medical concern as increasingly prevalent 
as diabetes. The generalization of the results of 
clinical trials designed in central countries, gen-
erally sponsored by the pharmaceutical industry, 
have their limitations, especially when the focus is 
placed on commercial interests to the detriment of 
the health of the most vulnerable sectors. 
ENDNOTES
a. This article is based on the final work presented 
at the Universidad Nacional de Lanús (UNLa) for 
the degree of Specialist in Epidemiology, entitled 
“Abordaje de la Diabetes entre los años 1980 y 
2010. Transformaciones y medicalización del 
cotidiano” [Diabetes management between 1980 
and 2010. Transformations and medicalization 
of the everyday]. The study was directed by Dr. 
Laura Recorder.
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